SCHEMBL3209241

SCHEMBL3209241

O=C(O)NS(=O)(=O)NCCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.60
CA7 P43166 1/20 0.60
CA9 Q16790 1/20 0.60
CA14 Q9ULX7 1/20 0.60
ALDH1A1 P00352 5/20 0.53
MAPT P10636 2/20 0.53
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
CYP3A4 P08684 1/20 0.51
GAA P10253 1/20 0.51
BLM P54132 1/20 0.51
GFER P55789 1/20 0.51
PMP22 Q01453 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
NPSR1 Q6W5P4 2/20 0.50
HTT P42858 1/20 0.50
AKR1C3 P42330 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3215854 0.85 TDP1 (0.56) CA12CA7CA9CA14ALDH1A1
SCHEMBL3209265 0.83 TBXAS1 (0.50) MEN1KMT2A
SCHEMBL6993873 0.81 CA12 (0.70) CA12CA7CA9CA14MAPT
SCHEMBL8244755 0.79 CA12 (0.75) CA12CA7CA9CA14ALDH1A1
SCHEMBL3220191 0.78 LMNA (0.56) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL3215905 0.77 ALDH1A1 (0.44) CA12CA7CA9CA14ALDH1A1
SCHEMBL1168754 0.77 ALDH1A1 (0.63) CA12CA7CA9CA14ALDH1A1
SCHEMBL3217657 0.76 NPC1 (0.50) CA12CA9LMNAMEN1KMT2A
SCHEMBL3195576 0.75 MTNR1A (0.53) ALDH1A1L3MBTL1NPSR1HTTMEN1
SCHEMBL1414871 0.73 CA1 (0.67) CA12CA7CA9CA14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 CA12 3251/4885CA7 1418/4885CA9 2144/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 CA12 3135/4885CA7 1554/4885CA9 2659/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 CA12 3251/4885CA7 1418/4885CA9 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.